<- Go Home

Akoya Biosciences, Inc.

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. Akoya Biosciences, Inc. was incorporated in 2015 and is headquartered in Marlborough, Massachusetts. As of July 8, 2025, Akoya Biosciences, Inc. operates as a subsidiary of Quanterix Corporation.

Market Cap

$64.4M

Volume

349.0K

Cash and Equivalents

$20.4M

EBITDA

-$30.0M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$49.4M

Profit Margin

61.74%

52 Week High

$3.42

52 Week Low

$0.93

Dividend

N/A

Price / Book Value

-10.92

Price / Earnings

-1.34

Price / Tangible Book Value

-1.69

Enterprise Value

$120.6M

Enterprise Value / EBITDA

-4.30

Operating Income

-$37.4M

Return on Equity

354.27%

Return on Assets

-17.49

Cash and Short Term Investments

$27.5M

Debt

$83.7M

Equity

-$5.9M

Revenue

$80.0M

Unlevered FCF

-$8.7M

Sector

Life Sciences Tools and Services

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches